Summary
Pieris AG (Pieris) is a development stage biotechnology company that develops Anticalin technology based products for the effective treatment of various diseases. The company offers Anticalin-based proteins, which are recombinant engineered human lipocalins, low-molecular weight polypeptides. Its product pipeline includes PRS-050, PRS-080, PRS-060, 300 Series-A, 300 Series-B, PRS-110 and PRS-NN. Pieris PRS-080 is a hepcidin antagonist to treat anemia and PRS-060 is an inhaled IL4Ra antagonist to treat asthma. The company also offers products in the areas of oncology, anemia, asthma and immune-oncology. Pieris is headquartered in Freising-Weihenstephan, Germany.
Pieris AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Pieris AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Pieris AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Pieris AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Pieris AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Pieris AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Pieris AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Pieris Raises USD8.2 Million in Venture Financing 10
Partnerships 12
Stelis Biopharma Enters Into Co-Development Agreement With Pieris Forge For Novel Anticalin Therapeutics 12
Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 13
Pieris And Sanofi Expand Agreement For Anticalin Therapeutics 14
Pieris Enters Into Drug Discovery Collaboration With Takeda San Francisco 15
Licensing Agreements 16
Pieris Enters Into Collaboration And Licensing Agreement With Daiichi Sankyo 16
Pieris Signs Licensing Agreement With Sanofi-Aventis And Sanofi Pasteur 18
Equity Offering 20
Pieris Completes Private Placement for USD13.5 Million 20
Pieris AG - Key Competitors 22
Key Employees 23
Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25
List of Tables
Pieris AG, Pharmaceuticals & Healthcare, Key Facts 1
Pieris AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Pieris AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Pieris AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Pieris AG, Deals By Therapy Area, 2010 to YTD 2016 8
Pieris AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Pieris Raises USD8.2 Million in Venture Financing 10
Stelis Biopharma Enters Into Co-Development Agreement With Pieris Forge For Novel Anticalin Therapeutics 12
Zydus Cadila Enters Into Co-Development Agreement With Pieris For Anticalin Therapeutics 13
Pieris And Sanofi Expand Agreement For Anticalin Therapeutics 14
Pieris Enters Into Drug Discovery Collaboration With Takeda San Francisco 15
Pieris Enters Into Collaboration And Licensing Agreement With Daiichi Sankyo 16
Pieris Signs Licensing Agreement With Sanofi-Aventis And Sanofi Pasteur 18
Pieris Completes Private Placement for USD13.5 Million 20
Pieris AG, Key Competitors 22
Pieris AG, Key Employees 23
List of Figures
Pieris AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Pieris AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Pieris AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Pieris AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Pieris AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Pieris AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Pieris AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Pieris AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8